Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion
Completed
- Conditions
- Hypertension
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT02022774
- Locations
- ๐ฐ๐ท
Jeonju Jesus Hospital, Jeonju, Korea, Republic of
๐ฐ๐ทChonnam National University Hospital, Gwangju, Korea, Republic of
๐ฐ๐ทWonkwang University Hospital, Iksan, Korea, Republic of
To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT01921946
- Locations
- ๐ฐ๐ท
Kyungpook National University Hospital, Daegu, Korea, Republic of
A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT01878201
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT01736488
- Locations
- ๐ฐ๐ท
Gachon University Gil Hospital, Incheon, Korea, Republic of
๐ฐ๐ทHallym University Medical Center, Anyang, Korea, Republic of
๐ฐ๐ทKangnam Severance Hospital, Seoul, Korea, Republic of
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657โK) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 293
- Registration Number
- NCT01672476
- Locations
- ๐ฐ๐ท
Severance Hospital, Seoul, Korea, Republic of
Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarbยฎ Tablet (Fimasartan) in Healthy Subjects
- First Posted Date
- 2012-08-23
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT01671020
- Locations
- ๐ฐ๐ท
Inje University Busan Paik Hospital, Busan, Korea, Republic of
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 420
- Registration Number
- NCT01518998
- Locations
- ๐ฐ๐ท
Samsung Medical Center, Seoul, Korea, Republic of
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 495
- Registration Number
- NCT01499368
Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 103
- Registration Number
- NCT01397214
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT01289886
ยฉ Copyright 2025. All Rights Reserved by MedPath